The Inflammatory Bowel Disease Treatment by The Business Research Company provides market overview across 60+ geographies in the seven regions - Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).
Learn More On The Inflammatory Bowel Disease Treatment Market:
According to The Business Research Company’s Inflammatory Bowel Disease Treatment , The inflammatory bowel disease treatment market size has grown strongly in recent years. It will grow from $23.49 billion in 2023 to $25.56 billion in 2024 at a compound annual growth rate (CAGR) of 8.8%. The growth in the historic period can be attributed to increased prevalence of inflammatory bowel disease, growing demand for biologics and immunomodulators, advancements in treatment options, rising geriatric population, increased awareness about the disease.
The inflammatory bowel disease treatment market size is expected to see strong growth in the next few years. It will grow to $36.63 billion in 2028 at a compound annual growth rate (CAGR) of 9.4%. The growth in the forecast period can be attributed to increasing investment in research and development activities, growing demand for biosimilars, rising incidence of inflammatory bowel disease in emerging markets, growing demand for personalized medicine, integration of precision medicine in ibd treatment. Major trends in the forecast period include increasing number of product launches and approvals, personalized dosing and treatment plans in ibd management, use of telemedicine for remote monitoring of ibd patients, exploration of microbiome-based therapies for ibd, adoption of value-based care models in ibd treatmen.
The rising prevalence of Crohn’s disease and ulcerative colitis is significantly driving the inflammatory bowel disease treatment market. Crohn’s disease and ulcerative colitis are types of inflammatory bowel diseases (IBD) that cause inflammation and ulcers (sores) in the digestive tracts. The rising cases of Crohn’s disease and ulcerative colitis are expected to boost demand for inflammatory bowel disease treatments, as they are widely used to reduce bowel inflammation and reduce and prevent medical complications. For instance, according to March 2022 research published in the United States National Library of Medicine, a US-based medical library, around 1.6 million Americans currently suffer from inflammatory bowel disease (Crohn’s disease or ulcerative colitis) and around 70,000 new cases of IBD are diagnosed every year in the USA. Hence, the rising prevalence of Crohn's disease and ulcerative colitis is expected to drive the inflammatory bowel disease treatment market growth.
Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=6704&type=smp
The inflammatory bowel disease treatment market covered in this report is segmented –
1) By Drug Class: Aminosalicylates, Corticosteroids, TNF inhibitors, IL inhibitors, Anti-integrin, JAK inhibitors, Other Drug Classes
2) By Type: Crohn's Disease, Ulcerative Colitis
3) By Route of Administration: Oral, Injectable
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
Technological advancement is a key trend gaining popularity in the inflammatory bowel disease treatment market. The key players in the inflammatory bowel disease treatment market are focusing on using technology such as artificial intelligence (AI) for the drug discovery process as well as offering advanced but new inflammatory bowel disease treatments. To attain their technological innovations, key players and technology companies are partnering to leverage each other's competencies and technology to develop new treatments and strengthen their key position in the market. For instance, in May 2021, CytoReason, an Israeli technology start-up developing a computational model of the human body, partnered with Ferring Pharmaceuticals, a Switzerland-based multinational pharmaceutical company to develop new inflammatory bowel disease treatments (IBD) using artificial intelligence technology during the drug discovery process. Ferring's medical expertise will be combined with CytoReason's artificial intelligence (AI) technology to create cell-centred illness models. The AI technology enables scientists to gain critical information on the body’s functioning and treats diseases at the cellular level.
The inflammatory bowel disease treatment market report table of contents includes:
1. Executive Summary
2. Inflammatory Bowel Disease Treatment Market Characteristics
3. Inflammatory Bowel Disease Treatment Market Trends And Strategies
4. Inflammatory Bowel Disease Treatment Market - Macro Economic Scenario
5. Global Inflammatory Bowel Disease Treatment Market Size and Growth
...................
31. Global Inflammatory Bowel Disease Treatment Market Competitive Benchmarking
32. Global Inflammatory Bowel Disease Treatment Market Competitive Dashboard
33. Key Mergers And Acquisitions In The Inflammatory Bowel Disease Treatment Market
34. Inflammatory Bowel Disease Treatment Market Future Outlook and Potential Analysis
35. Appendix
Read Related Reports:
https://goodprnews.com/critical-infrastructure-protection-global-market-size/
https://topprnews.com/critical-infrastructure-protection-global-market-share/
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
The inflammatory bowel disease treatment market is expected to register a CAGR of 2.5% during the forecast period due to the increasing patient pool, advances in medical technology, government initiatives for research on novel drugs discovery, and increasing prevalence of anxiety and depression.
Moreover, the increasing number of drugs in clinical trials and the growing popularity of prebiotic and probiotic foods are likely to result in market growth.
However, high capital investments required for the discovery of drugs, the unsatisfactory effectiveness of treatments, and stringent drug regulatory policies are restraining the growth of the inflammatory bowel disease treatment market.Request Sample Copy:https://www.marketresearchfuture.com/sample_request/6266Regional AnalysisThe Americas is expected to be the largest market for inflammatory bowel disease treatment owing to the increasing prevalence of anxiety and rising incidences of ulcerative colitis and Crohn’s disease.
The Centers for Disease Control and Prevention (CDC) has stated that about 1.3% of US adults (3 million) were diagnosed with IBD, either Crohn’s disease or ulcerative colitis, in 2015.
This can be attributed to the increasing prevalence of inflammatory bowel disease caused by a rising rate of alcohol abuse in adults, unhealthy lifestyle habits, and prevalence of anxiety and depression in adults.
The rising number of patients diagnosed with anxiety and depression, the increasing abuse of alcohol, and sedentary lifestyles are expected to result in a greater number of patients afflicted with inflammatory bowel disease, thus driving the demand for treatment.
